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Introduction
Small-intestinal bacterial overgrowth (SIBO) is a malabsorption syndrome associated with increased bacterial density above 10 5 colony-forming units per mL of smallintestinal aspirate and/or the presence of colonic-type species [1] . Previous studies have found that diseases associated with impaired gastrointestinal (GI) motility are predisposing factors for the development of SIBO [2] .
Associations between SIBO and irritable bowel syndrome [3] , non-alcoholic fatty liver disease [4] , Parkinson's disease [5] and systemic sclerosis [6] have been suggested in previous studies.
During the spinal cord injury (SCI) process, especially in the acute stage, there are several complications, such as pulmonary infection, GI function disorder, and spasm [7] . Deep vein thrombosis (DVT), which mostly occurs during the first 2 weeks after SCI, represents one of the most common and dangerous complications during this period [8, 9] . Paffrath et al. [10] reported that the occurrence of clinically apparent venous thromboembolism during posttraumatic hospitalization was associated with increased morbidity and mortality. Furthermore, bowel problems occur in 27-62% of SCI patients, and are often associated with depression or with the highest levels of injuries and the longest duration [11] . Interestingly, Fialho et al. [12] found that SIBO was associated with DVT in patients who were identified from the databank of the GI Motility Laboratory at the Cleveland Clinic. However, there are no published studies in the literature evaluating a possible role of quantitative changes in intestinal bacteria such as SIBO and the development of DVT in SCI patients. The aim of this study was to determine the frequency and risk factors for DVT and SIBO in SCI patients.
Patients and methods
All subjects were informed of the study protocol, which had been approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University. Written informed consent from all participants was provided according to the Declaration of Helsinki.
From January 2011 to December 2015, all consecutive patients with first-ever SCI within 24 h admitted to our hospital were included in this study. The exclusion criteria wdere: (i) confirmed malignant tumor; (ii) a former diagnosis of venous thrombosis (VT) or known abnormalities of any coagulation factor; (iii) other disorders or diseases, such as GI diseases, trauma, severe edema, febrile disorders, serious infections, and autoimmune diseases; (iv) any contraindications to heparin use or lower-limb mechanical compression; (v) medications that affect GI motility (such as prokinetics, anticholinergics, and tricyclic antidepressants), antibiotics, or any other drugs that affect the intestinal flora (such as laxatives); and (vi) survival time of < 3 months.
Study variables and outcome measurements
Detailed demographic and clinical data pertaining to SIBO and DVT were obtained. Demographic and clinical data, such as gender, age, race, body mass index (BMI), conventional vascular risk factors (hypertension, diabetes, hypercholesterolemia, atrial fibrillation, and coronary heart disease), smoking and drinking habits, diagnosis of chronic kidney disease (CKD), family history of VT (defined by asking the patient or their attendant), family history of inflammatory bowel disease (IBD), and associated GI conditions, were obtained. A history of genetic thrombophilia, including factor V Leiden mutation and prothrombin gene mutation, was also reviewed [1] . The severity of SCI was assessed on admission according to the American Spinal Injury Association (ASIA) impairment scale (from A to D) [13] . ASIA score assessments were performed with the patient by two trained medical students using a Chinese version. The primary outcomes were the frequency of DVT and SIBO in SCI patients and the associated risk factors for DVT in this sample at 3 months after admission.
Diagnostic criteria of DVT and SIBO
These patients were assessed for DVT with color doppler ultrasonography (CDUS), regardless of whether they were symptomatic or asymptomatic. As a standard protocol, CDUS was performed 3 months after injury (range: 88-95 days) and whenever clinically requested. Some patients with clinical symptoms were assessed for DVT by CDUS before that time. These patients underwent lower-limb mechanical compression with external sequential pneumatic compression or elastic stockings to prevent DVT. Real time B-mode ultrasonography was performed with a 7.5-MHz or a 5.0-MHz transducer. The common femoral vein and the popliteal vein were examined. All participants were scanned on the transverse plane.
The diagnosis of SIBO was made by use of the glucose hydrogen/methane breath test at 3 months after admission (range: 88-95 days). Patients were submitted according to a standard protocol. The glucose breath test was performed in the morning following oral hygiene with 0.05% chlorhexidine. The participations fasted for a period of 12 h prior to the test. The hydrogen/methane breath concentration was expressed in parts per million (p.p.m.) and measured by gas chromatography in basal conditions every 15 min for at least 3 h after the administration of an oral loading dose of glucose (50 g in 250 mL of sterile water). The test was considered to be positive for SIBO when more than one of the criteria was present: hydrogen and/or methane increase of 420 p.p.m. above the basal value, or hydrogen and/or methane increase of 412 p.p.m. between the minimum and maximum values after glucose ingestion [12, 14] .
Statistical analysis
Data are given as the percentage (number) or frequencies for discrete variables, and as medians (interquartile range [IQR]) for continuous variables. Values of the measured parameters were checked for a normal distribution by means of the Kolmogorov-Smirnov test prior to statistical analysis. The Mann-Whitney U-test was performed for the comparison between groups for continuous variables; in addition, a chi-square test was used for the comparison of proportions between groups. Multivariate logistic regression analysis was performed to assess the risk factors associated with DVT in SIBO patients. An automated stepwise variable selection method performed on 1000 bootstrap samples was used to choose the final multivariable model. Results were expressed as adjusted odds ratios (ORs) with the corresponding 95% confidence intervals (CIs). All statistical analyses were performed with SPSS version 20.0 (UIBM, Armonk, NY, USA). P < 0.05 denotes statistical significance.
Results

Patient characteristics and clinical variations
In this study, 469 patients were screened in the analysis, and 377 SCI patients were included and completed the 3-month follow-up (Fig. 1) . The median age was 48 years (IQR 35-57) years, and 51.2% were women; there was an equivalent distribution of females and males (51.2% versus 48.8%, respectively; P = 0.283). In our study, 81 (21.5%) of the patients had a family history of VT. According to the ASIA score at admission, the numbers of patients with grade A, B, C and D were 85, 90, 115, and 87, respectively. Cervical cord injuries without fracture were observed in 213 of 377 (56.5%) patients. In this study, no patient had received prophylactic antithrombotic treatment with low molecular weight heparin before the diagnosis of DVT.
Frequency of DVT in the total samples and in patients with SIBO
Seventy-six of the 377 SCI patients were DVT-positive (20.2%; 95% CI 16.1-24.2%), and 145 were SIBO-positive (38.5%; 95% CI 29.9-59.0%) by the glucose hydrogen/methane breath test. Twenty-three of the 76 patients were diagnosed before the 3-month time point, owing to clinical request. In our study, 59 patients (77.6%) received antithrombotic therapy after adiagnosis of DVT. In all of the 76 patients, DVT occurred in the lower extremities. Among the 76 DVT-positive patients, 60 were SIBO-positive and 16 were SIBO-negative. The difference was statistically significant (41.4% versus 6.9%; OR 5.99; 95% CI 3.15-9.33). The demographic and clinical characteristics of SIBO-positive and SIBO-negative SCI patients are shown in Table 1 . Genetic thrombophilia occurred in eight of 377 (2.1%) patients, with FV Leiden mutation being the only diagnosis found.
Comparison of demographic and clinical variables in patients with and without SIBO
There was no difference between the SIBO-positive and SIBO-negative patients with regard to age, race, smoking, race, BMI, CKD, hypertension, diabetes at baseline, hypercholesterolemia, atrial fibrillation, location of DVT, or ASIA score, as shown in Table 1 (P > 0.05 for all). SIBO-positive patients were more likely to be males (55.9% versus 44.4%; P = 0.030), to have a family history of IBD (21.4% versus 6.0%; P < 0.001) and to have a family history of VT (28.3% versus 17.2%; P = 0.011) than SIBO-negative patients. Among GI symptoms, SIBO positivity was significantly associated with bloating (52.4% versus 33.6%; P < 0.001) and flatulence (55.9% versus 40.9%; P = 0.005) ( Table 1) .
Comparison of demographic and clinical variables in patients with and without DVT SCI patients with DVT were more likely to have a family history of VT in their first-degree relatives (53.9% versus 13.3%; P < 0.001), a diagnosis of CKD (30.0% versus 10.6%; P < 0.001), hypertension (40.8% versus 27.9%; P = 0.032), and atrial fibrillation (17.1% versus 8.6%; P = 0.027). Among the 145 SIBO-positive patients, 60 were DVT-positive and 85 were DVT-negative. The difference was statistically significant (78.9% versus 28.2%; OR 2.88; 95% CI 2.12-4.47). There was no difference among DVT-positive and DVT-negative patients regarding ASIA score, smoking history, IBD, hospital admission in the past 3 months, surgery in the past 3 months, and GI symptoms ( Table 2) .
Multivariate analysis of variables in patients with and without DVT
In the stepwise multivariate logistic regression analysis, a family history of VT (OR 2.32; 95% CI 1.60-3.79; P = 0.002), CKD (OR 2.99; 95% CI 1.73-5.08; P < 0.001) and the presence of SIBO (OR 3.72; 95% CI 1.97-6.62; P < 0.001) remained associated with DVT when evaluated in the model with male sex, elderly age, hypertension, hypercholesterolemia, atrial fibrillation, and IBD (Table 3) .
Discussion
GI dysfunction [15] and VT [16] are well-known acute complications after SCI. In this study, we found that 20.2% and 38.5% of SCI patients suffered from DVT and SIBO during the 3-month follow-up period. Furthermore, we assessed the associations between SIBO and DVT in SCI patients. We found that the presence of SIBO (OR 3.72; 95% CI 1.97-6.62; P < 0.001) remained associated with DVT when evaluated in the multivariate model. Consistent with our results, Fialho et al. [12] suggested that SIBO was associated with DVT as an independent risk factor along with CKD and a family history of thromboembolic events in first-degree relatives.
One study suggested that DVT can develop in the very acute stage of SCI, and that the incidence increases with more severe paralysis [17] . However, in this study, no association between severity of SCI and DVT was found. Furthermore, the incidence of DVTs in SCI patients is suggested to be extremely variable, ranging from 4.8% to 30% [8, [18] [19] [20] . In our clinical work, thromboprophylaxis is only used in those SCI patients diagnosed with DVT, most of whom present with clinical symptoms. The probable reason for not using thromboprophylaxis as a standard of care in those patients is insufficient awareness about DVT among our workers. However, in our study, 76 SCI patients (20.2%) were diagnosed with DVT during the 3-month follow-up period, suggesting that thromboprophylaxis should be used as a standard of care for SCI patients. Similarly, two previous studies from China and South Korea reported that the incidence rates of DVT after SCI were 19.7% and 27.6%, respectively [7, 16] .
Previous studies have shown a higher incidence of DVT with a worse ASIA score. Masuda et al. [21] found that all DVT-positive patients with traumatic cervical spinal injuries had severe paralysis classified as C or greater on the ASIA Impairment Scale, and another study suggested that DVT can develop in the very acute stage of SCI and that the incidence increases with more severe paralysis [17] . In contrast to those findings, we did not find any correlation between DVT and ASIA score. It should be realized that our study is a single-center and small-sample (N = 377) study. Furthermore, patients who had more severe SCI and died before the 3-month follow-up period were not included in the study. Interestingly, in another small-sample study (N = 187), Rathore et al. [19] also found that there was no influence of ASIA grade (P = 0.1) on the occurrence of DVT. Finally, differences in subject samples, diagnostic and assessment methods and time of assessment may explain the general discrepancy between those studies. More studies should be carried out to explore the relationship between DVT and ASIA score in SCI patients. Some studies have suggested that patients undergoing surgery are at a risk for DVT [22, 23] . However, in this study, we found that there was no difference among DVT-positive and DVT-negative patients regarding surgery in the past 3 months (15.8% versus 12.3%; P = 0.418). In the clinical data collection, we just recorded whether or not there was surgery in the past 3 months, and did not obtain the time of surgery. In addition, the small nunber of positive samples in the two groups (12/37) reduced the validity of our results. SCI patients frequently have neurogenic bowel dysfunction, owing to the absence of central nervous system control over the GI system [24] . There are two different bowel dysfunction types in SCI patients: upper motor neuron syndrome and lower motor neuron bowel syndrome [25, 26] . However, there are no published studies in the literature evaluating a quantitative change in intestinal bacteria, such as SIBO, in SCI patients. Further studies should be carried out to address this issue. Interestingly, considering that SCI is a stressor altering a number of physiologic processes, Gungor et al. [24] hypothesized that bowel dysfunction and altered colonic transit time in SCI patients could lead to a significant change in the composition of the gut microbiome.
This observational study cannot determine the causal relationship between SIBO and DVT. Possible pathophysiologic explanations are offered for correlation interpretation. First, inflammatory states and higher levels of proinflammatory cytokines are known risk factors for DVT [12] . Previous studies have suggested that SIBO may also be implicated in the development of non-alcoholic steatohepatitis and Parkinson's disease through increased production of proinflammatory markers [27, 28] . Rabinovich et al. [29] found that inflammation markers such as ICAM-1 predict the risk of post-thrombotic syndrome after DVT. Second, conditions that increase bacterial translocation have been implicated in the development of VT through higher circulating levels of lipopolysaccharide (LPS) along with increased expression of Toll-like receptor 4 (TLR-4), an innate immune receptor that is responsible for LPS recognition [30] . LPS binding to TLR-4 causes procoagulatory activation and may predispose to DVT [27] .
Overall, SIBO has been associated with increased release of interleukin-8 and enhanced expression of TLR-4 [31] . SIBO may also be associated with gut inflammation and a proinflammatory state [32] . Importantly, this association can also be bidirectional, as patients with a higher risk for DVT often have increased levels of proinflammatory markers that may influence the gut immune system and alter the gut microbiome, thereby promoting the development of SIBO. Essentially, SIBO not only might represent a consequence of SCI-related GI dysfunction, but also might play a role in DVT progression. This association might be bidirectional. Further studies are needed to confirm a causal link between SIBO and DVT in SCI patients.
The results of this study are of interest because, to our knowledge, SIBO-associated and DVT-associated studies targeting SCI patients are non-existent, and our results might help explain the possible implications of SIBO in DVT. Another strong point of this study is that patients with SIBO may benefit from a lower threshold for venous ultrasound evaluation, even when presenting with subtle signs suggestive of DVT. Also, patients with DVT who have chronic GI complaints may benefit from testing and treatment for SIBO.
There are some limitations of this study that should be taken into consideration. The first is the lack of information about the dietary habits of our subjects and PM2.5 exposure. Major long-term dietary differences between SCI patients with and without SIBO could cause differences in the microbiome [33] . One study showed that PM2.5 exposure was associated with DVT and pulmonary embolism hospital admissions [34] . In addition, DVT might have existed in SCI patients when they were included in the study. It would be expected that a DVT at admission would increase SIBO. Thus, we could not determine the association of those factors with DVT and SIBO in SCI patients. The second weakness is in the assessment of SIBO itself, as there is no gold standard way to diagnose SIBO, and the accuracy of all current tests remains limited [35] . Third, patients who had more severe SCI and died before the 3-month follow-up period were not included. Patients with DVT or SIBO who died might have been excluded. In addition, we only screened lower-limb veins in this study. However, upper-limb DVT cannot be ruled out. The presence of some patients with upper-limb DVT might have affected our results. Fourth, recent studies demonstrated that there was a distinct perturbation of the composition of the gut microbiota in animal models of depression and chronic stress [36] . It would be interesting to analyze the relationship between the presence of SIBO and the existence of cognitive decline and DVT. However, in our study, we did not obtain information about cognitive decline. Therefore, we could not assess this relationship. Finally, this study shows greater SIBO in SCI patients with or without DVT; however, no data were provided about the pathogenesis of SIBO in DVT. In fact, the more interesting question would be whether SIBO is pathogenically involved in the development of DVT. However, the observational nature of the study prevents any conclusions being drawn about any cause-effect relationships. Consequently, we do not know whether higher SIBO might induce DVT, or whether its increase might result from the presence of DVT.
Conclusion
In summary, these data support an association between SIBO and DVT in SCI patients. We recommend that further studies should be carried out with respect to the mechanism of the relationship between SIBO and DVT. If it is possible to elucidate this, the prognosis of SCI patients with DVT might be improved. In addition, the incidence of DVT in SCI patients is 20.2%, indicating an underestimation of the incidence of DVT prior to the implementation of screening. The results suggest that, in the future, thromboprophylaxis should be used as standard care for SCI patients. 
